An observational study in Obesity & Overweight, sponsored by Cinnagen. Completed at 14 sites in Iran. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Cinnagen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered:
In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
11,529 studies on the registry are indexed under Obesity; 2,035 are open to participants now.
This study's enrollment of 175 is above the median of 115 across 2,157 observational studies indexed under Obesity.
Browse Obesity studies →Cinnagen is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.
Proportion of patients with ≥5% weight loss
Time frame: day 0, 180
Percent change in body weight from baseline
Time frame: day 0, 90
Absolute change in body weight from baseline
Time frame: day 0, 90
Percent change in body weight from baseline
Time frame: day 0, 180
Absolute change in body weight from baseline
Time frame: day 0, 180
Mean change in Body Mass Index from baseline
24.9\<BMI\<30 and more than 30 are considered overweight and obesity, respectively. More BMI decrease is related to the better response.
Time frame: day 0, 90, 180
Mean change in waist circumference from baseline
Time frame: day 0, 90, 180
Proportion of patients with ≥5% weight loss
Time frame: day 0, 90
Proportion of patients with ≥10% weight loss
Time frame: day 0, 90, 180
Proportion of patients with ≥15% weight loss
Time frame: day 0, 180
Assessment of the adverse events (including Treatment Emergent Adverse Events)
Time frame: during study period
Assessment of immunogenicity at screening, day 90, and day 180
Time frame: day 0, 90, 180
Ran from Nov 2025 to primary completion in Jun 2026, 7 months.
Of 45 industry-sponsored observational studies under Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 7 months is below that.
Counting every sponsor, half of 837 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cinnagen